Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02819999
Title A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Stemcentrx
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Aurora Colorado 80010 United States Details
Rocky Mountain Cancer Centers Denver Colorado 80218 United States Details
Cancer Institute of Florida Orlando Florida 32804 United States Details
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21231 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Oncology Hematology Care Cincinnati Ohio 45242 United States Details
University Hospital of Cleveland Cleveland Ohio 44106 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
University of Pittsburgh Pittsburgh Pennsylvania 15232 United States Details
Texas Oncology Fort Worth Texas 76104 United States Details
Texas Oncology San Antonio Texas 78258 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field